Recurrent Ovarian Cancer research hub

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

This study is testing a new drug, ubamatamab, alone or with cemiplimab, for recurrent ovarian or endometrial cancer. It aims to see how safe it is, how it works in the body, and if it can help treat these cancers.